Stocks · News reference
Genprex Partners With Roche Diagnostics To Validate Biomarkers For Patient Selection In Clinical Trials For Non-Small Cell Lung Cancer
Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker. Genprex's initial research demonstrated that high TROP2 H-scores and low
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 3, 2026, 11:11 AM
- Checked
- Aug 3, 2026, 11:11 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Genprex, Inc. (GNPX)
Filed: 2026-08-18 AccNo: 0001437749-26-028250 Size: 171 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgar12 Health Care Stocks Moving In Monday's After-Market Session
Gainers INVO Fertility (NASDAQ:IVF) stock moved upwards by 13.1% to $1.73 during Monday's after-market session. The company's market cap stands at $1.7 million. The company's, Q2 earnings came out today.
Read original at benzingaGenprex shares are trading lower. The company announced its collaboration with Roche Diagnostics to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer.
Read original at benzinga